FineTech Pharmaceutical
Developing Active Pharmaceutical Ingredients
Company Overview
Snapshot
Founded in January 1990 by Arie Gutman, FineTech Pharmaceutical operates with 11–50 employees. The company was acquired by OPKO Health in December 2011.
Business overview
FineTech Pharmaceutical specializes in the development and manufacturing of active pharmaceutical ingredients (APIs), focusing on bypassing process and polymorph patents. The company also provides analytical method development and patent analysis to expedite product market entry for its clients. Its product portfolio includes APIs such as Cabergoline and Latanoprost, with expertise in organic processes like multi-step synthesis and polymorph development. Operating in the Health Tech & Life Sciences sector, specifically within Pharmaceuticals, FineTech serves markets including Canada, Israel, the United States, and Europe.
Log in to access full profile ›Company Intelligence Q&A
- When was FineTech Pharmaceutical founded?
- FineTech Pharmaceutical was founded in January 1990.
- Who founded FineTech Pharmaceutical?
- FineTech Pharmaceutical was founded by Arie Gutman.
- What is FineTech Pharmaceutical's primary business?
- FineTech Pharmaceutical develops and manufactures active pharmaceutical ingredients (APIs), focusing on bypassing process and polymorph patents, and offers analytical method development and patent analysis.
- Which company acquired FineTech Pharmaceutical?
- FineTech Pharmaceutical was acquired by OPKO Health in December 2011.
- What products does FineTech Pharmaceutical offer?
- FineTech Pharmaceutical offers products such as Latanoprost, Cabergoline, Methylbenzethonium chloride, Nabilone, Travoprost, and Bimatoprost.